Stefan Zimmermann
斯蒂凡·齐默尔曼
MD
Medical Oncologist, Department of Medical Oncology肿瘤内科医师
👥Biography 个人简介
Stefan Zimmermann is a leading medical oncologist at Gustave Roussy specializing in thyroid cancers and molecularly driven head and neck tumors. He has made significant contributions to the clinical development of RET inhibitors (selpercatinib, pralsetinib) and BRAF/MEK combinations in thyroid malignancies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
RET Inhibitor Development
Contributed to pivotal LIBRETTO-001 and ARROW trials establishing selpercatinib and pralsetinib as standard therapies for RET-altered thyroid and lung cancers.
BRAF-Targeted Therapy in Thyroid Cancer
Advanced clinical use of dabrafenib plus trametinib in BRAF V600E-mutated anaplastic thyroid cancer, contributing to the first FDA approval in this lethal disease.
Representative Works 代表性著作
Selpercatinib in Patients with RET-Mutant Medullary Thyroid Cancer
New England Journal of Medicine (2020)
LIBRETTO-001 establishing selpercatinib as a highly active, selective RET inhibitor in medullary thyroid cancer with durable responses.
Vemurafenib in Patients with BRAFV600E-Positive Metastatic or Unresectable Papillary Thyroid Cancer Refractory to Radioiodine
Journal of Clinical Oncology (2015)
Demonstrated BRAF inhibitor activity in radioiodine-refractory papillary thyroid cancer, informing targeted therapy strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Robert L. Ferris
University of Pittsburgh Medical Center
David J. Adelstein
Cleveland Clinic Taussig Cancer Institute
Maura L. Gillison
MD Anderson Cancer Center
Kevin J. Harrington
Royal Marsden NHS Foundation Trust / Institute of Cancer Research
关注 斯蒂凡·齐默尔曼 的研究动态
Follow Stefan Zimmermann's research updates
留下邮箱，当我们发布与 Stefan Zimmermann（Gustave Roussy Cancer Campus）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment